



**HAL**  
open science

## **Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib**

Maxime Vanmechelen, Diether Lambrechts, Thomas van Brussel, Annelies Verbiest, Gabrielle Couchy, Patrick Schoffski, Herlinde Dumez, Philip Debruyne, Evelyne Lerut, Jean-Pascal Machiels, et al.

### ► To cite this version:

Maxime Vanmechelen, Diether Lambrechts, Thomas van Brussel, Annelies Verbiest, Gabrielle Couchy, et al.. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. *Clinical Genitourinary Cancer*, 2019, 17 (2), pp.e235-e246. 10.1016/j.clgc.2018.11.002 . inserm-02532766

**HAL Id: inserm-02532766**

**<https://inserm.hal.science/inserm-02532766>**

Submitted on 22 Oct 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**Fibroblast Growth Factor Receptor-2 polymorphism rs2981582 is correlated with progression-free survival and overall survival in patients with metastatic clear-cell renal cell carcinoma treated with sunitinib**

Maxime Vanmechelen<sup>1</sup>, Diether Lambrechts<sup>2,3</sup>, Thomas Van Brussel<sup>2,3</sup>, Annelies Verbiest<sup>1</sup>, Gabrielle Couchy<sup>4</sup>, Patrick Schöffski<sup>1</sup>, Herlinde Dumez<sup>1</sup>, Philip R. Debruyne<sup>5</sup>, Evelyne Lerut<sup>6</sup>, Jean-Pascal Machiels<sup>7</sup>, Vincent Richard<sup>8</sup>, Maarten Albersen<sup>9</sup>, Vincent Verschaeve<sup>10</sup>, Stéphane Oudard<sup>11</sup>, Arnaud Méjean<sup>12</sup>, Pascal Wolter<sup>13</sup>, Jessica Zucman-Rossi<sup>4</sup>, Benoit Beuselinck<sup>1,4</sup>.

(1) Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

(2) Laboratory for Translational Genetics, Department of oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

(3) Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium.

(4) Inserm U674 Génomique fonctionnelle des tumeurs solides, Université Paris-5 René Descartes, Rue Juliette Dodu 27, 75010 Paris, France.

(5) Department of Medical Oncology, AZ Groeninge, President Kennedylaan 4, 8500 Kortrijk, Belgium, and Faculty of Health, Social Care & Education, Anglia Ruskin University, Chelmsford, U.K.

(6) Department of Pathology, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

(7) Department of Medical Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, 1200 Bruxelles, Belgium.

(8) Department of Medical Oncology, CHU Ambroise Paré, Boulevard Kennedy 2, 7000 Mons, Belgium.

(9) Department of Urology, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

(10) Department of Medical Oncology, Grand Hôpital de Charleroi, Grand Rue 3, 6000 Charleroi, Belgium.

(11) Department of Medical Oncology, Georges Pompidou European Hospital, Université Paris-5 René Descartes, Rue Leblanc 20, 75015 Paris, France.

(12) Department of Urology, Georges Pompidou European Hospital, Université Paris-5 René Descartes, Rue Leblanc 20, 75015 Paris, France.

(13) Department of Medical Oncology, St. Nikolaus-Hospital Eupen, Hufengasse 4-8, 4700 Eupen, Belgium.

**CORRESPONDING AUTHOR:** Benoit Beuselinck, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium, tel +32-16-346900, fax +32-16-346901, e-mail benoit.beuselinck@uzleuven.be

**KEYWORDS:** clear-cell renal cell carcinoma, sunitinib, outcome, single nucleotide polymorphisms, fibroblast growth factor receptor

### **MICRO-ABSTRACT**

We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast-growth-factor-receptor-2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13% of the patients, was associated with shorter progression-free survival and overall survival.

### **CLINICAL PRACTICE POINTS**

Biomarkers predicting outcome on vascular-endothelial-growth-factor-receptor tyrosine kinase inhibitors (VEGFR-TKIs) in metastatic clear-cell renal cell carcinoma are lacking. We have found rs2981582, a polymorphism in the fibroblast-growth-factor-receptor-2 (FGFR2), to be a potential biomarker associated with progression-free survival and overall survival on the VEGFR-TKI sunitinib in metastatic clear-cell renal cell carcinoma. In our series of 154 patients, TT-variant carriers had a poorer outcome compared to CT/CC-carriers: median progression-free survival was 8 versus 15 months ( $p=0.0007$ ) and median overall survival 22 versus 33 months ( $p=0.04$ ), respectively. Moreover, median shrinkage of selected tumor target lesions during treatment with sunitinib was -16% versus -31% ( $p=0.002$ ). On multivariate analysis, rs2981582 remained an independent predictor of progression-free survival and overall survival. Previously, the same impact was shown in metastatic clear-cell renal cell carcinoma patients treated with the VEGFR-TKI pazopanib. TT-variant carriers might have increased angiogenesis through the FGFR2-pathway, leading to escape of the tumor when treated with sunitinib or pazopanib. These findings, when validated, might have a clinical impact in future: they could be used for patient counselling on prognosis and might also explain the efficacy of FGFR-blockers in m-ccRCC.

## **ABSTRACT**

**Background:** There are no validated markers that predict response or resistance in metastatic clear-cell renal cell cancer (m-ccRCC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) such as sunitinib and pazopanib. Recently, single nucleotide polymorphism (SNP) rs2981582 in Fibroblast Growth Factor Receptor 2 (FGFR2) was found to be associated with clinical outcome in m-ccRCC patients treated with pazopanib and sunitinib. We aimed to validate these findings in patients treated with sunitinib.

**Materials and methods:** Germline DNA was collected in patients with m-ccRCC starting first-line systemic therapy with sunitinib. SNP rs2981582 in FGFR2 C>T was genotyped. Association of the genotype with response rate (RR), tumor shrinkage, median progression free survival (mPFS) and median overall survival (mOS) was studied.

**Results:** We collected clinical data from 154 patients with available germline DNA. Baseline prognostic markers were well balanced between both subgroups. Patients with the TT-genotype had a poorer outcome compared to patients with the CT/CC-genotype. Median shrinkage of selected tumor target lesions during treatment with sunitinib was -16% versus -31% ( $p=0.002$ ), mPFS was 8 versus 15 months ( $p=0.0007$ ) and mOS 22 versus 33 months ( $p=0.04$ ), respectively. On multivariate analysis, rs2981582 remained an independent predictor of PFS (HR 2.858;  $p<0.0001$ ; 95%CI 1.659-4.923) and OS (HR of 1.795;  $p=0.049$ ; 95%CI 1.003-3.212).

**Conclusion:** Polymorphism rs2981582 in FGFR2 is correlated to PFS and OS in m-ccRCC patients treated with sunitinib. Prospective validation of the impact of this SNP is warranted.

## INTRODUCTION

Clear-cell renal cell carcinoma (ccRCC) is characterized by ubiquitous loss of a functional Von Hippel Lindau (VHL) protein, caused by mutation, promotor hypermethylation or loss of heterozygosity (1, 2). This results in an increase in hypoxia inducible factor (HIF) (3) and, among other effects, subsequent activation of vascular endothelial growth factor (VEGF) dependent angiogenesis. Targeted therapies directed against the VEGF-pathway are the current standard of care as first-line treatment of m-ccRCC patients (4, 5). Apart from bevacizumab, which is an anti-VEGF antibody, these therapies are tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, axitinib, cabozantinib or sorafenib, inhibiting VEGF-receptors (VEGFR) and other molecular targets. Sunitinib and pazopanib are most often used in first-line therapy (6, 7). Clinical responses are highly variable and even patients who initially respond well will ultimately develop secondary resistance (8). Unfortunately, there are no validated predictive biomarkers for response or resistance in m-ccRCC patients treated with VEGFR-TKIs.

The VEGF-dependent pro-angiogenic pathway targeted by these therapies has been the object of several studies searching for predictive biomarkers. VHL-mutations are not correlated with efficacy (9). On a transcriptomic level, upregulation of angiogenesis-related genes has been associated with better response to VEGFR-TKIs (10-13). Finally, several studies have linked SNPs in genes encoding proteins in the VEGF-pathway with outcome in m-ccRCC patients treated with sunitinib (14-17). However, validation of these findings in independent patient series has been challenging (18, 19).

Activation of VEGF-independent neo-angiogenesis, for instance through the FGFR-pathway, is suggested as one of the putative mechanisms of resistance to VEGF-directed therapy (20). When the VEGF-dependent pro-angiogenic pathway is blocked by VEGFR-TKIs, neo-angiogenesis and tumor growth could continue through the FGFR-pathway. Therefore, FGFR-blockers such as dovitinib and lenvatinib have been tested in m-ccRCC (21, 22). The TT-variant of SNP rs2981582 C>T in FGFR2 has been associated with increased FGFR2 gene expression in breast cancer cell lines (23).

The possible impact of SNP rs2981582 in FGFR2 on outcome in m-RCC patients treated with VEGFR-TKIs was previously shown in patients treated with pazopanib. In 380 patients treated in first-line with pazopanib in three studies, among them the pazopanib pivotal trial (7), Xu et al. showed the negative impact of the TT-variant in rs2981582 on PFS ( $p=0.053$ ) (24). In 241 patients included in the pazopanib pivotal trial, rs2981582 was associated with mOS ( $p=0.008$ ; HR 1.40; 95%CI 1.09-1.81) (25), favoring

CT/CC-carriers. We previously published the impact of rs2981582 on outcome in m-RCC patients treated with sunitinib. We compared outcome in 23 patients with the CC-genotype and 12 with the TT-genotype. mPFS was 14 versus 7.5 months, respectively ( $p=0.012$ ), but no impact on OS was shown (17). Outcome of the CT-carriers was not studied, because our analysis at that moment was based on an abstract of Xu et al. comparing OS in CC- versus TT-carriers treated with pazopanib.

The aim of the present study was to validate the impact of SNP rs2981582 in a larger series of m-ccRCC patients treated with sunitinib as first-line VEGF-targeted therapy and to study more in detail the impact of the three different genotype combinations (CC, CT and TT) on outcome.

## MATERIALS AND METHODS

For this retrospective study, germ-line DNA samples were collected in the “CIT-rein” kidney tumor bank (frozen normal kidney tissue) in patients treated at the University Hospitals Leuven (peripheral blood samples) and in patients included in the Belgian multicentric METASUN study (peripheral blood samples). The French-Belgian multicentric CIT-rein kidney tumor bank contains frozen kidney tumor samples collected at 20 academic hospitals in Belgium and France. Eligible patients could have received cytokines as systemic treatment for kidney tumors before starting sunitinib as a monotherapy. Patients who received previous treatment with any other targeted therapy before starting sunitinib were excluded. The study was approved by the medical ethics review boards of all participating institutions, and signed informed consent was obtained from all patients. DNA was isolated at INSERM U1162 in Paris, France, from fresh frozen normal kidney tissue sampled in the nephrectomy specimen using the Qiaquick extraction kit (Qiagen, Valencia, CA, USA) and quantified by fluorometry (Fluoroskan Thermo Labsystems, Cergy-Pontoise, France). DNA was isolated from peripheral blood at the Vesalius Research Center in Leuven, Belgium, with the Qiagen DNA kit (Qiagen, Valencia, CA, USA) and final DNA concentration quantified with Nanodrop (Nanodrop, Wilmington, DE, USA). High-throughput SNP genotyping was performed at the Vesalius Research Center in Leuven, Belgium, using the Sequenom MassArray platform (Sequenom, San Diego, CA, USA) (26). Genotyping analysis was performed by investigators blinded for the clinical data.

All patients were treated in routine clinical practice. The treating oncologist could change treatment approach concerning drug schedule, dose-reduction policy, and timing of radiological assessments in accordance with current local practice guidelines. CT thorax-abdomen was performed in most cases every two cycles of sunitinib. All the patients started their sunitinib therapy at the standard sunitinib dose of 50 mg/day four weeks on two weeks off. Commonly used prognostic factors were assessed: sarcomatoid dedifferentiation, presence of bone metastases and the variables included in the IMDC score (International Metastatic Renal Cell Carcinoma Database Consortium): baseline neutrophil count, baseline platelets and hemoglobin, calcium, time between initial diagnosis and start of systemic therapy and Karnofsky performance status (27). Primary kidney tumors were also classified according to the molecular ccrcc1-4 classification as described previously (13). This expression-profile based classification has a prognostic value in patients treated with metastasectomy (28) and a predictive value in patients treated with sunitinib (13) or pazopanib (29).

Clinical data were collected at 19 different sites in France and Belgium. The main objective of the study was to investigate the impact of rs2981582 on outcome in m-ccRCC patients treated with sunitinib and to investigate whether this impact would be prognostic or predictive.

The primary endpoints of the study were PFS, RR and tumor shrinkage. The secondary endpoint was OS. In fact, OS can be influenced by sequential therapies administered after first-line sunitinib, particularly immune checkpoint inhibitors, that have an activity mechanism thought to be independent of angiogenesis. We defined PFS as the interval between the first day on treatment with sunitinib and the date of radiological progressive disease or death. Patients who had not progressed at database closure were censored at last follow-up. OS was defined as the interval between the first day on sunitinib and the date of death or last date of follow-up. Objective response was assessed by treating doctors using Response Evaluation Criteria in Solid Tumors (RECIST). We studied not only the impact of RECIST-categories (complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD)), but also the precise percentage of RECIST tumor shrinkage compared to baseline, whenever available. The precise percentage of tumor shrinkage can give additional and more precise information compared to the RECIST categories CR-PR-SD-PD. On one hand, although the difference between a SD with 29% of tumor shrinkage and a PR with 31% of shrinkage is not an important difference in shrinkage, patients are classified in another response category. On the other hand, two patients with tumor shrinkage of 35% and 95% will both be classified in the PR-group, but the response has been more important in the latter case.

The impact of rs2981582 was studied in a discovery and a validation cohort. The discovery cohort was composed of the 88 patients included in our previous publication (17), in which we reported the impact of SNPs in several genes such as VEGFR3, ABCB1, NR1/3, NR1/2, PDGFRA and FGFR2. However, in this previous publication, concerning FGFR2, we only reported outcome in CC-carriers (n=23) compared to TT-carriers (n=12), because we aimed to replicate data presented in 2011 in an abstract by Xu et al. comparing OS in CC- versus TT-carriers treated with pazopanib. Outcome for CT-carriers was not reported in this previous study. Now, we aimed to study more in detail the impact of the three different genotype combinations (CC, CT and TT) on outcome in our series of patients genotyped in 2011. The validation cohort was composed of new patient samples genotyped from 2013 on.

All patient characteristics were tested in univariate fashion to study the association with mPFS and mOS using Kaplan–Meier estimates and in a multivariate model using Cox proportional hazards. Fisher exact test was used to compare percentages and student's t-test was applied for comparison of tumor shrinkage between carriers of different genotypes. All variables that did correlate with PFS and OS on univariate

analysis with a p-value of  $<0.2$  were included in the multivariate analysis. Results with a p-value of  $<0.05$  were considered as significant in the univariate and multivariate analyses. Statistical analyses were conducted using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) and XLSTAT software (Addinsoft, Paris, France).

## RESULTS

### Included patients

We included 154 patients who started sunitinib between November 2005 and July 2016 and closed the follow-up database in September 2017. This series included the 35 patients assessed in the project published earlier (17). Table 1 shows the clinical characteristics of patients included in this project. Mean age at diagnosis was 59 years (range 30-80) with a male predominance (71%). The majority of patients were of Caucasian origin. 55% had Fuhrman grade IV ccRCCs on the initial nephrectomy specimen or biopsy. According to IMDC prognostic criteria, 15% of patients were categorized into the favorable risk group, 61% had intermediate and 24% poor risk. In 85 patients, the primary tumor was classified according to the ccrc1-4 classification. At the time of final analysis, 121 (79%) patients had reached progression and 108 (70%) had died. The median follow-up was 47.5 months (range 2.0 – 239.0 months) after the start of sunitinib. The global mPFS was 13 months and mOS 30 months. Best RECIST response assessment was available in 147 patients. 11/147 (7%) patients had a CR, 60/147 (41%) patients a PR, 53/147 (36%) SD and 23/147 (16%) PD as best response. In 6 patients, there was a clinical benefit, but response assessment was poorly defined in the medical records, and as a consequence, it was unclear whether the best response was either PR or SD in these 6 patients. One patient died after one month of treatment with sunitinib. These results are comparable to phase III and expanded access response data (4, 30). Precise percentage of RECIST tumor shrinkage was available in 103 patients. 44/154 (29%) patients carried the FGFR2 rs2981582 CC genotype, 90/154 (58%) were heterozygous (CT genotype) and the remaining 20 patients (13%) had two T alleles. The allele distribution was as follows: T was present in 42.2% and C in 57.8%. This is coherent with the minor allele frequency reported on dbSNP (<https://www.ncbi.nlm.nih.gov/SNP/>) (45.6%). Around 75% of the patients received a second-line therapy. Among them, 29 patients were treated with immune checkpoint inhibitors (two in the TT-group and 27 in the CC+CT-group).

### Discovery cohort

The discovery cohort was composed of the patient with samples genotyped in 2011: 12 TT-, 52 CT- and 23 CC-carriers. The genotype was unknown in one patient. mPFS was 8, 19, and 16 months, respectively, in TT-, CT- and CC-carriers ( $p=0.03$ ). As Kaplan-Meier curves for PFS were overlapping in CT- and CC-carriers, we pooled CT- and CC-carriers. mPFS was 8 versus 18 months the TT- and CC/CT-carriers,

respectively ( $p=0.006$ ; HR 0.3062 95%CI 0.1326-0.7071). mOS was 23 versus 31 months the TT- and CT/CC-carriers ( $p=0.22$ ; HR 0.6320 95%CI 0.3055-1.307)(Figure 1).

### **Validation cohort**

The validation cohort was composed of 67 new patients, genotyped from 2013 on: 7 TT-carriers, 38 CT-carriers and 22 CC-carriers. mPFS was 6, 12, and 12 months, respectively, in TT-, CT- and CC-carriers ( $p=0.06$ ). Again, Kaplan-Meier curves for PFS were overlapping in CC- and CT-carriers. When CT- and CC-carriers were pooled, mPFS was 6 versus 12 months for TT- and CT/CC-carriers ( $p=0.02$ ; HR 0.2363 95%CI 0.07142-0.7819). mOS was 13 versus 34 months the TT- and CT/CC-carriers ( $p=0.03$ ; HR 0.2444 95%CI 0.06865-0.8703)(Figure 1).

### **Total cohort**

In the total cohort, mPFS was 8 and 15 months for TT- and CT/CC-carriers, respectively ( $p=0.0007$ ). mOS was 22 and 33 months for the TT- and CT/CC-carriers, respectively ( $p=0.04$ ) (Figure 1). PR rate was 37% in patients with the TT-genotype compared to 50% in patients with the CT/CC-genotype. This difference was not significant. Complete responses ( $n=11$ ) were only noticed in the CT/CC-genotype subgroup. Median tumor shrinkage was -16% for patients with the TT-genotype versus -31% for patients with the CT/CC-genotype ( $p=0.002$ ) (Figure 2).

When comparing the three different genotypes separately, mPFS was 8, 15 and 14 months for patients with the TT-, CT- and CC-genotype, respectively ( $p=0.005$ ). The curves of CT- and CC-carriers were overlapping (Figure 3). PR rate was 35%, 51% and 48%, for TT-, CT and CC-carriers, respectively, however, these differences were not significantly different. PD as best response was observed in 21%, 13% and 16% of the patients, respectively. The median percentage of tumor shrinkage was -16%, -35% and -28% for patients with the TT-, CT- and CC-genotype, respectively ( $p=0.09$ ). mOS was 22, 35 and 19 months, respectively ( $p=0.04$ ). The OS-curve of the CC-carriers lied in between the curves of the CT-carriers and TT-carriers (Figure 3).

## **Multivariate analysis**

In the multivariate analysis, we included the commonly used prognostic markers that were significant on univariate analysis (the presence of bone metastases, baseline neutrophil count, baseline platelet count, sarcomatoid dedifferentiation, Karnofsky Performance Status, baseline hemoglobin levels, baseline lactate dehydrogenase activity and time between nephrectomy to systemic therapy <12 months (Table 2)). Table 1 shows that all baseline patient characteristics usually associated with prognosis, including IMDC score, were well balanced between TT- and CT/CC-carriers, except baseline LDH (above 1.5\*upper limit of normal: 21% in TT- versus 4% in CT/CC-carriers;  $p=0.02$ ). However, median baseline LDH-levels were identical in TT- and CT/CC-carriers (232,0 versus 247.5 U/L,  $p=0.8$ ). In the multivariate analysis, rs2981582 remained as independently associated with PFS with a HR of 2.858 ( $p<0.0001$ ; 95%CI 1.659-4.923) and with OS with a HR of 1.795 ( $p=0.049$ ; 95%CI 1.003-3.212) (Table 3). LDH levels were not associated with PFS (HR 0.677 (95%CI 0.240-1.910);  $p=0.46$ ) nor OS (HR 0.531 (95%CI 0.181-1.562);  $p=0.25$ ). Supplementary Figure 1 shows that the negative impact of the TT-variant on PFS can be observed in all IMDC risk group patients. Thus, the poor outcome for TT-patients seems not to be driven by the higher frequency of elevated LDH nor by IMDC risk stratification.

## **Supplementary internal validation**

As an additional internal validation of our results, we analyzed the impact of rs2981582 in the subgroup of patients treated at Belgian ( $n=102$ ) and at French sites ( $n=52$ ) patients included in this study. An identical significant impact on mPFS was observed in both subgroups (Supplementary Figure 2).

## DISCUSSION

The aim of this study was to investigate the impact of SNP rs2981582 in FGFR2 in patients with m-ccRCC treated with sunitinib as first-line VEGFR-targeted therapy.

In this series of 154 patients, we found a statistically and clinically significant impact of the TT-variant on outcome. Compared to patients with the CT/CC-genotype, TT patients had significantly poorer mPFS and mOS and less important tumor shrinkage on sunitinib. rs2981582 remained as an independent predictor of mPFS and mOS on multivariate analysis. The impact of rs2981582 was stronger on PFS than on OS, but we have to consider the impact of subsequent therapy lines, among them immune checkpoint inhibitors, on OS.

Considering merely the correlation with mPFS and mOS, it is impossible to differentiate if the impact of rs2981582 is prognostic or predictive. The impact of rs2981582 would be prognostic, if a longer mPFS and mOS are the consequence of a more indolent disease in CC/CT-carriers and a more aggressive disease in TT-carriers. The impact of rs2981582 would be predictive, if a longer mPFS and mOS are the result of an improved efficacy of sunitinib in CC/CT-carriers compared to TT-carriers. In the latter case, the polymorphism should also be strongly correlated to tumor shrinkage. Based on our findings, although rs2981582 was correlated to median tumor shrinkage, we still cannot state that rs2981582 is a predictive biomarker for response on sunitinib. Indeed, even in TT-carriers, partial responses have been noticed in our patient series.

Similar data in literature are scarce. rs2981582 in FGFR2 was previously found to be associated with treatment outcome in m-ccRCC patients treated in first-line with pazopanib. rs2981582 was associated with mPFS ( $p=0.053$ ) (24) and with mOS ( $p=0.008$ ; HR 1.40; 95%CI 1.09-1.81) (25), favoring CT/CC-carriers.

The validation of findings on the prognostic or predictive value of specific SNPs in m-ccRCCs treated with VEGFR-TKIs has been challenging (31). The most concordant results were found in SNPs in the efflux pump ABCB1 (17, 32-35) and in interleukin-8 (25, 36). Findings on the impact of SNPs in VEGFR1 (rs9582036) (16) and VEGFR3 (rs307826) (17, 37), although similarly shown in independent series, were not confirmed in other patient cohorts (18, 19). However, findings concerning the impact of rs2981582 are

now coherent in 154 patients treated with sunitinib and 380 with pazopanib, totalizing 534 patients. This is an argument in favor of the robustness of these findings, which now should be validated in further independent patient series.

FGFR2 amplifications and mutations have been described in multiple cancer types (38). However, FGFR2 mutations are rare in ccRCCs (2) and data on FGFR2 amplification are scarce. FGFR2 is located on chromosome 10q26 and encodes a receptor tyrosine kinase that is involved in multiple processes like cell growth, invasiveness, mortality and VEGF-independent angiogenesis (39). FGFR2 amplifications have been reported in up to 10% of gastric cancers, most of which are diffuse-type with relatively poor prognosis (40). In a series of 125 patients with invasive ductal breast carcinoma, a significant association between cytoplasmic FGFR2 expression levels and tumor size was shown. Higher expression levels of FGFR2 were associated with lower OS and disease-free survival (41). Finally, the association with rs2981582 and breast cancer susceptibility is another argument in favor of a (patho)physiologic impact of this polymorphism. In a meta-analysis, FGFR2 was confirmed as a breast cancer susceptibility gene, and various variants of FGFR2 are significantly associated with breast cancer risk. For rs2981582, 39 studies for a total of 93.000 patients and 107.000 controls were evaluated. The corresponding odds ratio (OR) for developing breast cancer in heterozygous individuals was 1.21 whereas homozygous individuals (TT) carried an OR of 1.48 compared to people carrying the wild type (CC) ( $p < 0.001$ ) (42).

The TT-polymorphism in rs2981582 906C>T leads to increased transcription and expression of FGFR2 (23) and thus possibly to increased VEGF-independent angiogenesis. When VEGF inhibitors successfully block angiogenic pathways that rely on VEGF, other pro-angiogenic factors and pathways, such as the FGF-FGFR-axis, can be activated and be responsible for further vessel growth and disease progression (kinase switch theory). The result is a stimulation of endothelial cell-, fibroblast- and tumor cell growth and function. Unfortunately, FGFR2 mRNA-expression data were not available. However, most probably, it will not be FGFR2-expression in the primary kidney tumor, but in metastases resisting to sunitinib which could be correlated to the FGFR2-genotype. Unfortunately, tissue samples of metastases resisting to systemic therapy are usually only rarely available.

FGFR inhibitors such as lenvatinib and dovitinib, have been tested in m-ccRCC in clinical studies. Lenvatinib is a TKI targeting FGFR1,2,3,4 and VEGFR. Lenvatinib was tested in a phase II trial in patients progressing on a previous VEGF-targeted therapy. Patients received lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus or single agent treatment with these two agents. Lenvatinib plus

everolimus or lenvatinib alone resulted in a PFS benefit compared to everolimus in monotherapy. The RR was 43% in patients receiving lenvatinib plus everolimus, compared to 6% in patients receiving everolimus in monotherapy. This RR with lenvatinib was higher than the RR usually seen in second line VEGFR-TKIs (22, 43). Dovitinib is a TKI targeting, besides the VEGFR, also FGFR1 and FGFR3. Dovitinib was tested in a phase III study as a third-line therapy in m-ccRCC patients treated in first-line with VEGF-targeted therapy and in second-line with everolimus. Patients were randomized between dovitinib and sorafenib. Surprisingly, mPFS and mOS were similar in both treatment arms and the study was considered negative. The results of this study have challenged the hypothesis that resistance to anti-VEGF-TKIs is mainly due to FGFR activation (21). Possibly, the difference in efficacy between lenvatinib and dovitinib can be explained by a larger FGFR-inhibition by lenvatinib.

Our pharmacogenomics study has several potential limitations. First, it was a retrospective, uncontrolled analysis of patients treated in several centers without a central protocol dictating the treatment schedule and dose modifications or the timing of radiological assessments. Secondly, because our patients were mainly Caucasian, the relevance of these polymorphisms needs to be assessed in other ethnic groups because of possible genetic heterogeneity. Finally, at this moment these findings cannot be used for patient selection for treatment with VEGFR-TKIs. However, these results provide further evidence that FGFR2 is involved in resistance to VEGFR-TKIs in m-ccRCC patients.

## **CONCLUSIONS**

Polymorphism rs2981582 in FGFR2 is correlated to outcome in m-ccRCC patients treated with sunitinib. The TT-genotype is associated with poorer PFS, poorer OS and reduced target lesion shrinkage during treatment compared to the CC- and CT-genotype. Prospective validation of this SNP is now warranted.

## **GRANT SUPPORT**

Benoit Beuselinck received a grant from the Fondation Martine Midy (Paris, France) (2009-2010), the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Belgium) (2011-2013) and an unrestricted research grant from Pfizer (2014). Diether Lambrechts is supported by the Stichting Tegen Kanker. Evelyne Lerut received funds from Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Belgium) and Stichting tegen Kanker. Annelies Verbiest received an Emmanuel van der Schueren grant from Stichting Kom op tegen Kanker.

## **CONFLICTS OF INTEREST**

Stéphane Oudard received honoraria from Novartis, Pfizer, Roche, BMS and Bayer. Patrick Schöffski received one institutional travel grant from Pfizer related to clinical research in non-clear cell renal cell carcinoma. Jean Jacques Patard is a consultant and principal investigator in Pfizer trials. Diether Lambrechts served on advisory boards from Roche, Sanofi, Bayer, Novartis, Boehringer and Eli-Lilly and received honoraria for this. Benoit Beuselinck received honoraria from Amgen, Pfizer, Janssen, Ipsen and Bayer. Benoit Beuselinck is an investigator of the EudraCT: 2011-006085-40/METASUN trial supported by Pfizer. He received honoraria from IPSEN, AMGEN, Novartis and Pfizer. The other authors have no conflicts of interest to declare.

## REFERENCES

1. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat Genet.* 2013;45(8):860-7.
2. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature.* 2013;499(7456):43-9.
3. Fakih M, Schiff D, Erlich R, Logan TF. Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: a series of six cases. *Annals of oncology : official journal of the European Society for Medical Oncology.* 2001;12(8):1173-7.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2009;27(22):3584-90.
5. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *The New England journal of medicine.* 2013;369(8):722-31.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *The New England journal of medicine.* 2007;356(2):115-24.
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2010;28(6):1061-8.
8. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. *European urology.* 2013.
9. Kim BJ, Kim JH, Kim HS, Zang DY. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. *Oncotarget.* 2017;8(8):13979-85.
10. You D, Song SH, Cho YM, Lee JL, Jeong IG, Song C, et al. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. *World J Urol.* 2015;33(1):111-8.
11. Garcia-Donas J, Leandro-Garcia LJ, Gonzalez Del Alba A, Morente M, Alemany I, Esteban E, et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* 2013;24(9):2409-14.
12. Beuselinck B, Verbiest A, Couchy G. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. *Acta Oncol.* 2017.
13. Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. *Clinical cancer research : an official journal of the American Association for Cancer Research.* 2015;21(6):1329-39.


14. Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. *The Lancet Oncology*. 2011;12(12):1143-50.
15. Dornbusch J, Walter M, Gottschalk A, Obaje A, Junker K, Ohlmann CH, et al. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. *J Cancer Res Clin Oncol*. 2016;142(6):1171-82.
16. Beuselinck B, Jean-Baptiste J, Schoffski P, Couchy G, Meiller C, Rolland F, et al. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. *BJU international*. 2016;118(6):890-901.
17. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. *British journal of cancer*. 2013;108(4):887-900.
18. Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, et al. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. *Oncotarget*. 2017;8(1):1204-12.
19. Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. *Cancer chemotherapy and pharmacology*. 2014;74(4):739-50.
20. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell*. 2005;8(4):299-309.
21. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. *The Lancet Oncology*. 2014;15(3):286-96.
22. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *The Lancet Oncology*. 2015;16(15):1473-82.
23. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. *PLoS Biol*. 2008;6(5):e108.
24. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(18):2557-64.
25. Xu CF, Johnson T, Garcia-Donas J, Choueiri TK, Sternberg CN, Davis ID, et al. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. *British journal of cancer*. 2015;112 Suppl:1190-8.
26. Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. *Nature biotechnology*. 2012;30(1):61-8.

27. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2009;27(34):5794-9.
28. Verbiest A, Couchy G, Job S, Caruana L, Lerut E, Oyen R, et al. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. *European urology*. 2018.
29. Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. *Clinical genitourinary cancer*. 2017.
30. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. *British journal of cancer*. 2015;113(1):12-9.
31. Beuselink B, Zucman-Rossi J. Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up? *Nature reviews Urology*. 2015;12(8):424-6.
32. Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, et al. CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. *European urology*. 2015.
33. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2011;17(3):620-9.
34. Chu YH, Li H, Tan HS, Koh V, Lai J, Phyo WM, et al. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. *PloS one*. 2015;10(8):e0134102.
35. Beuselink B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. *Acta oncologica*. 2014:1-10.
36. Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, et al. Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. *Clinical genitourinary cancer*. 2017;15(5):526-33.
37. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. *The Lancet Oncology*. 2011;12(12):1143-50.
38. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2012;18(7):1855-62.
39. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nature reviews Cancer*. 2010;10(2):116-29.

40. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. *Cancer research*. 2008;68(7):2340-8.
41. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. *Journal of surgical oncology*. 2012;105(8):773-9.
42. Cui F, Wu D, Wang W, He X, Wang M. Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis. *Breast cancer research and treatment*. 2016;155(2):313-35.
43. Sacre A, Barthelemy P, Korenbaum C, Burgy M, Wolter P, Dumez H, et al. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Acta oncologica*. 2016;55(3):329-40.


**FIGURE 1: KAPLAN-MEIER ESTIMATES SHOWING THE IMPACT OF rs2981582 ON PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN THE DISCOVERY COHORT, THE VALIDATION COHORT AND THE TOTAL PATIENT SERIES.**

**PFS (%) DISCOVERY COHORT**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 |
|--------|----|----|----|----|----|----|----|
| CC+CT  | 74 | 59 | 46 | 34 | 25 | 20 | 18 |
| TT     | 13 | 9  | 3  | 2  | 2  | 2  | 1  |

**PFS (%) VALIDATION COHORT**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 |
|--------|----|----|----|----|----|----|----|
| CC+CT  | 60 | 42 | 28 | 15 | 9  | 5  | 2  |
| TT     | 7  | 4  | 1  | 0  | 0  | 0  | 0  |

**PFS (%) TOTAL SERIES**




| Months | 0   | 6   | 12 | 18 | 24 | 30 | 36 |
|--------|-----|-----|----|----|----|----|----|
| CC+CT  | 134 | 101 | 74 | 49 | 34 | 25 | 20 |
| TT     | 20  | 13  | 4  | 2  | 2  | 2  | 1  |

**OS (%) DISCOVERY COHORT**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 | 42 |
|--------|----|----|----|----|----|----|----|----|
| CC+CT  | 74 | 68 | 59 | 49 | 45 | 39 | 30 | 27 |
| TT     | 13 | 13 | 12 | 11 | 6  | 5  | 3  | 3  |

**OS (%) VALIDATION COHORT**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 | 42 |
|--------|----|----|----|----|----|----|----|----|
| CC+CT  | 60 | 54 | 46 | 35 | 30 | 26 | 14 | 12 |
| TT     | 7  | 5  | 4  | 3  | 2  | 1  | 0  | 0  |

**OS (%) TOTAL SERIES**




| Months | 0   | 6   | 12  | 18 | 24 | 30 | 36 | 42 |
|--------|-----|-----|-----|----|----|----|----|----|
| CC+CT  | 134 | 122 | 105 | 84 | 75 | 65 | 44 | 39 |
| TT     | 20  | 18  | 14  | 14 | 8  | 6  | 3  | 3  |

FIGURE 2: WATERFALL PLOT FOR TUMOR SHRINKAGE ON SUNITINIB CORRELATED TO rs2981582 GENOTYPE. ANALYSIS ON 103 PATIENTS IN WHOM THE PRECISE PERCENTAGE OF TUMOR SHRINKAGE WAS KNOWN.




**FIGURE 3: KAPLAN-MEIER ESTIMATES SHOWING THE IMPACT OF THE THREE GENOTYPES (CC, CT AND TT) OF rs2981582 ON PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL**

**PFS (%)**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 |
|--------|----|----|----|----|----|----|----|
| CC     | 44 | 31 | 25 | 12 | 9  | 8  | 7  |
| CT     | 90 | 70 | 49 | 37 | 25 | 17 | 13 |
| TT     | 20 | 13 | 4  | 2  | 2  | 2  | 1  |

**OS (%)**




| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 | 42 | 48 |
|--------|----|----|----|----|----|----|----|----|----|
| CC     | 44 | 40 | 35 | 24 | 19 | 16 | 11 | 9  | 7  |
| CT     | 90 | 82 | 70 | 60 | 56 | 49 | 33 | 30 | 24 |
| TT     | 20 | 18 | 14 | 14 | 8  | 6  | 3  | 3  | 3  |



- IMDC good risk CC+CT (25 months)
- - IMDC good risk TT (23 months)
- IMDC intermediate risk CC+CT (14 months)
- - IMDC intermediate risk TT (8 months)
- IMDC poor risk CC+CT (15 months)
- - IMDC poor risk TT (3.5 months)


**SUPPLEMENTARY FIGURE 2: INTERNAL VALIDATION: KAPLAN-MEIER ESTIMATES SHOWING THE SAME IMPACT OF rs2981582 ON PROGRESSION-FREE SURVIVAL IN BELGIAN (PANEL A) AND FRENCH (PANEL B) PATIENTS**

**PFS (%) BELGIAN PATIENTS**



| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 |
|--------|----|----|----|----|----|----|----|
| CC/CT  | 90 | 66 | 47 | 30 | 20 | 13 | 9  |
| TT     | 12 | 8  | 3  | 1  | 1  | 1  | 1  |

**PFS (%) FRENCH PATIENTS**



| Months | 0  | 6  | 12 | 18 | 24 | 30 | 36 |
|--------|----|----|----|----|----|----|----|
| CC/CT  | 44 | 35 | 27 | 19 | 13 | 12 | 11 |
| TT     | 8  | 5  | 1  | 1  | 1  | 1  | 0  |

**TABLE 1: PATIENT CHARACTERISTICS AT DIAGNOSIS AND AT THE START OF SUNITINIB TREATMENT AND BASELINE CLINICAL AND BIOCHEMICAL PARAMETERS ASSOCIATED WITH PFS AND OS**

| AT INITIAL DIAGNOSIS                        |  | TOTAL (=154)  | CC+CT (n=134) | TT (n=20)   | p-value     |
|---|--|---------------|---------------|-------------|-------------|
| Male  |  | 71% (109/154) | 73% (98/134)  | 55% (11/20) | 0.12        |
| Age (mean, range)                           |  | 59 (30-80)    | 59 (35-78)    | 62 (30-80)  |             |
| Ethnic origin                               | Caucasian                                  | 90% (139/154) | 91% (122/134) | 85% (17/20) | 0.42        |
|   | Unknown                                    | 10% (15/154)  | 9% (12/134)   | 15% (3/20)  | 0.42        |
| M1 (synchronous metastases)                 |  | 57% (85/150)  | 56% (73/131)  | 63% (12/19) | 0.63        |
| Fuhrman                                     | Grade 4                                    | 55% (82/148)  | 56% (72/128)  | 50% (10/20) | 0.64        |
| Sarcomatoid dedifferentiation               | ≥25%                                       | 4% (5/138)    | 3% (4/120)    | 6% (1/18)   | 0.51        |
| AT THE START OF SUNITINIB                   |  |               |               |             |             |
| Karnofsky Performance Status                | ≤ 70                                       | 16% (25/153)  | 17% (23/133)  | 10% (2/20)  | 0.53        |
| Neutrophils                                 | >4.500/mm <sup>3</sup>                     | 46% (70/151)  | 44% (58/131)  | 60% (12/20) | 0.23        |
| Platelets                                   | >400.000/mm <sup>3</sup>                   | 18% (27/153)  | 18% (24/133)  | 15% (3/20)  | 1.00        |
| Hemoglobin                                  | Low (<11.5 g/dl (women) or <13 g/dl (men)) | 40% (61/153)  | 38% (51/133)  | 50% (10/20) | 0.34        |
| LDH   | >1.5ULN                                    | 6% (9/149)    | 4% (5/130)    | 21% (4/19)  | <b>0.02</b> |
| Corrected Calcium                           | >10 mg/dl                                  | 10% (11/112)  | 11% (11/98)   | 0% (0/14)   | 0.35        |
| Time from nephrectomy to systemic treatment | <12 months                                 | 65% (100/153) | 63% (84/133)  | 80% (16/20) | 0.21        |
| Immunotherapy before sunitinib              |  | 18% (27/153)  | 19% (25/134)  | 11% (2/19)  | 0.53        |
| Site of metastasis                          | Lung                                       | 75% (116/154) | 76% (102/134) | 70% (14/20) | 0.58        |
|   | Liver                                      | 20% (31/154)  | 19% (26/134)  | 25% (5/20)  | 0.56        |
|   | Bone                                       | 36% (55/154)  | 36% (48/134)  | 35% (7/20)  | 1.00        |
|   | Brain                                      | 8% (13/154)   | 9% (12/134)   | 5% (1/20)   | 1.00        |
| Molecular ccrcc1-4 classification           | Ccrcc1                                     | 35% (30/85)   | 36% (26/73)   | 33% (4/12)  | 0.88        |
|   | Ccrcc2                                     | 46% (39/85)   | 44% (32/73)   | 58% (7/12)  | 0.35        |
|   | Ccrcc3                                     | 4% (3/85)     | 4% (3/73)     | 0% (0/12)   | 0.47        |
|   | Ccrcc4                                     | 15% (13/85)   | 16% (12/73)   | 8% (1/12)   | 0.47        |
| IMDC prognosis                              | Favorable                                  | 15% (22/150)  | 15% (20/132)  | 11% (2/18)  | 1.00        |
|   | Intermediate                               | 61% (92/150)  | 61% (80/132)  | 67% (12/18) | 0.80        |
|   | Poor                                       | 24% (36/150)  | 24% (32/132)  | 22% (4/18)  | 1.00        |

| <b>SUBSEQUENT THERAPY UPON PROGRESSION ON SUNITINIB</b> |                        |             |             |
|---|------------------------|-------------|-------------|
| Sunitinib ongoing                                       | 6/98 (6%)              | 6/87 (7%)   | 0/11 (0%)   |
|   | Axitinib               | 27/98 (28%) | 25/87 (29%) |
|   | Cabozantinib           | 2/98 (2%)   | 2/87 (2%)   |
|   | Everolimus             | 22/98 (22%) | 18/87 (21%) |
|   | Nivolumab              | 9/98 (9%)   | 8/87 (9%)   |
| Second line therapy                                     | Pazopanib              | 3/98 (3%)   | 3/87 (3%)   |
|   | Sorafenib              | 8/98 (8%)   | 8/87 (9%)   |
|   | Temsirolimus           | 1/98 (1%)   | 1/87 (1%)   |
|   | Experimental treatment | 2/98 (2%)   | 2/87 (2%)   |
|   | All                    | 74/98 (74%) | 67/87 (77%) |
| Palliative/died   | 18/98 (18%)            | 14/87 (16%) | 4/11 (36%)  |
| Not available   | 56                     | 47          | 9           |

LDH: lactate dehydrogenase activity. ULN: upper limit of normal. IMDC: The International Metastatic Renal Cell Carcinoma Database Consortium.

**TABLE 2: UNIVARIATE ANALYSIS - ASSOCIATION BETWEEN SNP AND OUTCOME**

| VARIABLES  |     | Number of patients | Median PFS (months) | p-value       | Median OS (months) | p-value           |
|--|-----|--------------------|---------------------|---------------|--------------------|-------------------|
| FGFR2 rs2981582 906C>T                           | No  | 134                | 15                  | <b>0.0007</b> | 33                 | <b>0.04</b>       |
|  | Yes | 20                 | 8                   |               | 22                 |                   |
| Bone metastases                                  | No  | 99                 | 14                  | 0.098         | 34                 | <b>0.01</b>       |
|  | Yes | 55                 | 11                  |               | 19                 |                   |
| Neutrophil count >4.500/mm <sup>3</sup>          | No  | 139                | 14                  | <b>0.0001</b> | 31                 | <b>&lt;0.0001</b> |
|  | Yes | 13                 | 3                   |               | 6                  |                   |
| Platelet count >400.000/mm <sup>3</sup>          | No  | 133                | 14                  | <b>0.01</b>   | 34                 | <b>0.0002</b>     |
|  | Yes | 20                 | 7                   |               | 13.5               |                   |
| Sarcomatoid dedifferentiation ≥25%               | No  | 133                | 14                  | <b>0.0006</b> | 30                 | <b>0.008</b>      |
|  | Yes | 5                  | 2                   |               | 14                 |                   |
| Karnofsky Performance Status ≤70                 | No  | 128                | 14                  | <b>0.007</b>  | 31                 | <b>0.006</b>      |
|  | Yes | 25                 | 8                   |               | 14                 |                   |
| Hemoglobin low <11.5 g/dl women or <13 g/dl men  | No  | 70                 | 16                  | 0.097         | 35                 | 0.18              |
|  | Yes | 83                 | 11                  |               | 23                 |                   |
| LDH >1.5 ULN                                     | No  | 140                | 14                  | 0.11          | 31                 | 0.15              |
|  | Yes | 9                  | 10                  |               | 22                 |                   |
| Corrected Calcium >10mg/dl                       | No  | 137                | 13                  | 0.46          | 30                 | 0.48              |
|  | Yes | 11                 | 21                  |               | 29                 |                   |
| Time from nephrectomy to systemic treatment <12m | No  | 53                 | 15                  | 0.08          | 42                 | <b>0.01</b>       |
|  | Yes | 100                | 12                  |               | 27                 |                   |

In univariate analysis, median PFS and median OS were estimated by Kaplan-Meier and p-values are derived from a log-rank test. SNP: single nucleotide polymorphism. PFS: progression free survival. OS: overall survival. FGFR2: fibroblast growth factor receptor 2. LDH: lactate dehydrogenase activity. ULN: upper limit of normal.

**TABLE 3: MULTIVARIATE ANALYSIS FOR PFS AND OS**

| <b>Variable</b>                                  | <b>p-value</b>     | <b>Hazard ratio</b> | <b>95% Confidence interval</b> |
|--|--------------------|---------------------|--------------------------------|
| <b>MULTIVARIATE ANALYSIS FOR PFS</b>             |                    |                     |                                |
| Neutrophil count >4.500/mm <sup>3</sup>          | <b>0,002</b>       | <b>2,878</b>        | <b>1,450 – 5,709</b>           |
| Platelet count >400.000/mm <sup>3</sup>          | <b>0,010</b>       | <b>2,129</b>        | <b>1,196 – 3,790</b>           |
| Karnofsky Performance Status ≤70                 | <b>0,013</b>       | <b>1,965</b>        | <b>1,150 – 3,357</b>           |
| Sarcomatoid dedifferentiation ≥25%               | <b>0,019</b>       | <b>3,414</b>        | <b>1,223 – 9,532</b>           |
| FGFR2 rs2981582 TT polymorphism                  | <b>0,000</b>       | <b>2,858</b>        | <b>1,659 – 4,923</b>           |
| <b>MULTIVARIATE ANALYSIS FOR OS</b>              |                    |                     |                                |
| Neutrophil count >4.500/mm <sup>3</sup>          | <b>&lt; 0,0001</b> | <b>5,774</b>        | <b>2,806 – 11,878</b>          |
| Platelet count >400.000/mm <sup>3</sup>          | <b>0,001</b>       | <b>2,619</b>        | <b>1,447 – 4,741</b>           |
| Karnofsky Performance Status ≤70                 | <b>0,022</b>       | <b>1,993</b>        | <b>1,104 – 3,598</b>           |
| Time from nephrectomy to systemic treatment <12m | <b>0,014</b>       | <b>1,827</b>        | <b>1,131 – 2,951</b>           |
| Bone metastases                                  | <b>0,008</b>       | <b>1,844</b>        | <b>1,174 – 2,896</b>           |
| FGFR2 rs2981582 TT polymorphism                  | <b>0,049</b>       | <b>1,795</b>        | <b>1,003 – 3,212</b>           |